chartexchange

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results

GlobeNewswire Inc. | Nov 16, 2026 7:00 AM EST

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quar

Read original article